Hurry up and wait: Is accelerated approval of new cancer drugs in the best interests of cancer patients?

被引：8
|
作者：
Schilsky, RL [1 ]
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 20期
关键词：
D O I：
10.1200/JCO.2003.07.942
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3718 / 3720
页数：3
相关论文
共 50 条
  • [21] Time to Confirmatory Study Initiation After Accelerated Approval of Cancer and Noncancer Drugs in the US
    Jazowski, Shelley A.
    Vaidya, Avi U.
    Donohue, Julie M.
    Dusetzina, Stacie B.
    Sachs, Rachel E.
    JAMA INTERNAL MEDICINE, 2023, 183 (07) : 737 - 739
  • [22] TIME TO APPROVAL OF NOVEL CANCER MEDICINES GRANTED ACCELERATED APPROVAL AND IMPLICATIONS FOR REFORM OF THE ACCELERATED APPROVAL PATHWAY
    Hwang, Thomas
    Tibau, Ariadna
    JOURNAL OF UROLOGY, 2024, 211 (05): : E941 - E941
  • [23] APPROVAL OF CANCER DRUGS EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
    Duran, Carlos E.
    Canas, Martin
    Christiaens, Thierry
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 367
  • [24] A roadmap for accelerated drug approval in breast cancer?
    Perez-Garcia, Jose
    Cortes, Javier
    LANCET ONCOLOGY, 2012, 13 (09): : 850 - 851
  • [25] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [26] First Treatment for Urothelial Cancer Granted Accelerated Approval
    不详
    BIOPHARM INTERNATIONAL, 2020, 33 (03) : 10 - 10
  • [27] CANCER DRUGS SECURE SPEEDY APPROVAL IN CANADA
    VOGT, C
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (21) : 1620 - 1622
  • [28] New drugs for patients with pancreatic cancer
    Von Hoff, DD
    Bearss, D
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (06) : 621 - 627
  • [29] NEW DRUGS FOR INFECTIONS IN PATIENTS WITH CANCER
    HUGHES, WT
    CANCER, 1992, 70 (04) : 959 - 965
  • [30] Do post-approval phase III trials for accelerated approved cancer drugs violate equipoise?
    Lurie, A. J.
    Djulbegovic, B.
    Nebeker, J. R.
    Angelotta, C.
    Gordon, L. I.
    Raisch, D. W.
    Yarnold, P. R.
    Carson, K. R.
    McKoy, J. M.
    Bennett, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 307S - 307S
12345